Will the Supect’s insurance benefit end the cruelty of domestic anticancer drugs?

A chronic myeloid leukemia(CML) treatment, ‘Supect(generic name: radotinib)’ has drawn attention if it would end the cruelty of domestic anticancer drugs as approved as a primary treatment with the health insurance benefit. The cruelty has been continued by the first domestic anticancer drug, Sunpla, Milican and Camtobell.

A domestic anticancer drug, Sunpla has not been manufactured from now o...